Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo

Cancer Research

Volumn 60, Issue 2, 2000, Pages 253-258

  Bronte, Vincenzo ^a   Apolloni, Elisa ^a   Ronca, Roberto ^a   Zamboni, Paola ^a   Overwijk, Willem W ^b   Surman, Deborah R ^b   Restifo, Nicholas P ^b   Zanovello, Paola ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINASE RELATED PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CONTROLLED STUDY; IMMUNOTHERAPY; LYMPHOCYTE; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINIA VIRUS; VITILIGO;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON TYPE I; INTRAMOLECULAR OXIDOREDUCTASES; KILLER CELLS, NATURAL; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDES; PREGNANCY PROTEINS; VACCINES, SYNTHETIC; VITILIGO;

EID: 0034650262     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Henderson, R. A., and Finn, O. J. Human tumor antigens are ready to fly. Adv. Immunol., 62: 217-256, 1996.
2. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
3. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10: 281-287, 1999.
4. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
5. Weber, L. W., Bowne, W. B., Wolchok, J. D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J. J., and Houghton, A. N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Investig., 102: 1258-1264, 1998.
6. Naftzger, C., Takechi, Y., Kohda, H., Hara, I., Vijayasaradhi, S., and Houghton, A. N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA, 93: 14809-14814, 1996.
7. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B., Rosenberg, S. A., and Restifo, N. P. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
8. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med., 182: 1609-1614, 1995.
9. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., and Ravetch, J. V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA, 95: 652-656, 1998.
10. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A., and Yang, J. C. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med., 185: 453-459, 1997.
11. Tuting, T., Gambotto, A., DeLeo, A., Lotze, M. T., Robbins, P. D., and Storkus, W. J. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther., 6: 73-80, 1999.
12. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Rohas, A. M., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim., 22: 195-201, 1988.
13. Winder, A., Kobayashi, T., Tsukamoto, K., Urabe, K., Aroca, P., Kameyama, K., and Hearing, V. J. The tyrosinase gene family-interactions of melanogenic proteins to regulate melanogenesis. Cell. Mol. Biol. Res., 40: 613-626, 1994.
14. Moss, B., and Earl, P. L. Expression of proteins in mammalian cells using vaccinia viral vector. In: F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (eds.), Current Protocols in Molecular Biology, Vol. 2, pp. 16.15.1-16.19.11. New York: John Wiley and Sons. Inc., 1998.
15. Barth, R. J., Jr., Mule, J. J., Spiess, P. J., and Rosenberg, S. A. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp. Med., 173: 647-658, 1991.
16. Hartikka, J., Sawdey, M., Cornefert-Jensen, F., Margalith, M., Barnhart, K., Nolasco, M., Vahlsing, H. L., Meek, J., Marquet, M., Hobart, P., Norman, J., and Manthorpe, M. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther., 7: 1205-1217, 1996.
17. Ashton-Rickardt, P. G., Bandeira, A., Delaney, J. R., Van Kaer, L., Pircher, H. P., Zinkernagel, R. M., and Tonegawa, S. Evidence for a differential avidity model of T cell selection in the thymus. Cell, 76: 651-663, 1994.
18. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
19. Irvine, K. R., Rao, J. B., Rosenberg, S. A., and Restifo, N. P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol., 156: 238-245, 1996.
20. Bronte, V., Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A., and Restifo, N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol., 154: 5282-5292, 1995.
21. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
22. Merimsky, O., Baharav, E., Shoenfeld, Y., Chaitchik, S., Tsigelman, R., Cohen-Aloro, D., and Fishman, P. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol. Immunother., 42: 297-302, 1996.
23. van Elsas, A., Hurwitz, A. A., and Allison, J. P. Combination immunotherapy of B 16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med., 190: 355-366, 1999.
24. Rosato, A., Zambon, A., Milan, G., Ciminale, V., D'Agostino, D. M., Macino, B., Zanovello, P., and Collavo, D. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther., 8: 1451-1458, 1997.
25. Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., and Hill, A. V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med., 4: 397-402, 1998.